Table 2.
Target AUC0–24/MIC and AUC0–24 for TDM of moxifloxacin and levofloxacin in patients with MDR-TB
| Fluoroquinolone | Pulmonary MDR-TB | Target AUC0–24/MIC* | Target AUC0–24 (mg*h/L) | ||
| MGIT | 7H10/11 | LJ | |||
| Moxifloxacin | Standard disease | >100 | >50 | >25 | >40 |
| Severe disease or comorbidities | >100 | >50 | >25 | >60† | |
| Levofloxacin | Standard disease | >150 | >150‡ | >75 | >150 |
| Severe disease or comorbidities | >150 | >150‡ | >75 | >200† | |
Standard disease is defined as non-cavitary and regular disease on the radiograph. Severe disease is defined as cavitary or extensive disease on the radiograph.
*MIC varies depending on growth media; mycobacteria growth indicator tubes (MGIT), Middlebrook 7H10/7H11, and Lowenstein-Jensen (LJ) agar.
†Target AUC0–24/MIC at site of cavity; therefore, higher AUC0–24 is required.
‡Levofloxacin critical concentration of 7H11 was extrapolated to 7H10.
AUC, area under the concentration–time curve; LJ, Lowenstein-Jensen; MDR-TB, multidrug-resistant tuberculosis; MGIT, mycobacteria growth indicator tubes; MIC, minimal inhibitory concentration; TDM, therapeutic drug monitoring.